Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06574568 is registered in ClinicalTrials.gov with Excyte Biopharma Ltd as lead sponsor.

NCT NCT06574568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06574568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Excyte Biopharma Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 14, 2024
Completion date
June 30, 2027
Enrollment
70 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma